MedTrace Logo

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

NCT05760560 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2023-04-14

No results posted yet for this study

Summary

This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.

Conditions

  • Postoperative Residual Curarization

Interventions

DRUG

Sugammadex

At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Chang-Hoon Koo · Seoul National University Bundang Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2023-08-31
Completion
2024-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05760560 on ClinicalTrials.gov